BioInvent International (BINV) Corporate presentation summary

Platform and pipeline

• F.I.R.S.T. combines proprietary target discovery, phenotypic screening, phage display and immunology expertise to identify oncology targets and antibodies.

• Four clinical programs span BI-1808, targeting TNFR2, and BI-1206, targeting FcγRIIB, across ovarian cancer, CTCL, NHL, NSCLC and uveal melanoma.

• Phase 2 trials are ongoing; operations were funded through Q1 2027, and the presentation outlined clinical milestones for 2026–2027.

BI-1808 in ovarian cancer

• In a Phase 2a study of BI-1808 plus pembrolizumab, ORR was 24% and DCR 56% among 25 evaluable patients; mPFS was 10.3 months at the 20 April 2026 cutoff.

• Responses included 1 CR, 5 PRs and 8 SD; 9 of 25 patients remained on treatment, with PFS still maturing and final readout expected in H2 2026.

• The heavily pretreated cohort had a median of 5 prior treatment lines, and all patients had received platinum-based therapy.

• BI-1808 monotherapy showed a CR in an ovarian cancer case; the presentation described its mechanism as depleting Tregs and activating macrophages to support CD8+ T-cell antitumor activity.

• A preliminary base-case forecast estimated BI-1808 peak sales of $1.72 billion across seven major markets for platinum-resistant ovarian cancer; assumptions were described as early and untested in market research.

BI-1808 in T-cell lymphoma

• In Phase 2a CTCL monotherapy data, ORR was 40% and DCR 93% among 15 evaluable patients; responses included 5 PRs and 1 CR, with stable disease ongoing for over 2 years.

• BI-1808 plus pembrolizumab showed a 50% ORR and 75% DCR among 8 evaluable CTCL patients; 4 PRs were reported.

• The CTCL program included 20 patients treated with 1,000 mg BI-1808 monotherapy, followed by a combination cohort; dose optimization compared 250 mg and 1,000 mg monotherapy.

• The presentation highlighted orphan drug designation for T-cell lymphoma and Fast Track designation for CTCL.